Tibet Cheezheng Tibetan Medicine Co., Ltd is a China-based company, principally engaged in the research, development, manufacture and distribution of Tibetan medicines. The Company primarily offers medicines under emplastrum, ointment, granule, crude drugs and others. The Company's products include external pain relieving series, including Cheezheng Xiaotong emplastrum, Qingpeng ointment and Baimai ointment, as well as oral medicine series. The Company distributes its products within domestic market and to overseas markets.

Employees

3,170

Sector

Pharmaceuticals

Calendar

24/04 - Earnings release - Annual 2025

More about the company

Quotes

Date	Price	Change	Volume
22/26/22	23.10 ¥	-0.35%	13,64,306
21/26/21	23.18 ¥	0.00%	12,51,304
20/26/20	23.18 ¥	-0.52%	14,57,720
17/26/17	23.30 ¥	-0.60%	17,01,542
16/26/16	23.44 ¥	-0.04%	17,00,926

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. Other stock markets 22/04/2026			5-day change	1st Jan Change
23.10 ^CNY	-0.35%		-1.49%	-2.37%

13/02	Tibet Cheezheng Tibetan Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
21/01	Tibet Cheezheng Tibetan Medicine's Shiwei Gentian Flower Capsules Becomes Second-Level Protected TCM Variety	MT

Capitalization	1.35TCr 197.36Cr 168.41Cr 154.47Cr 146.1Cr 269.61Cr 19TCr 275.6Cr 1.81TCr 714.56Cr 8.87TCr 740.22Cr 725Cr 31TCr	P/E ratio 2023	20.5x	P/E ratio 2024	19.5x
Enterprise value	1.22TCr 178.33Cr 152.17Cr 139.58Cr 132.02Cr 243.62Cr 17TCr 249.03Cr 1.64TCr 645.68Cr 8.01TCr 668.86Cr 655.11Cr 28TCr	EV / Sales 2023	5.42x	EV / Sales 2024	4.3x
Free-Float	10.76%	Yield 2023	2.13%	Yield 2024	1.78%

13/02	Tibet Cheezheng Tibetan Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
21/01	Tibet Cheezheng Tibetan Medicine's Shiwei Gentian Flower Capsules Becomes Second-Level Protected TCM Variety	MT
05/12	Tranche Update on Tibet Cheezheng Tibetan Medicine Co., Ltd.'s Equity Buyback Plan announced on March 3, 2025.	CI
05/12	Tibet Cheezheng Tibetan Medicine Co., Ltd.'s Equity Buyback announced on March 3, 2025, has closed with 5,821,355 shares, representing 1.06% for CNY 137.44 million.	CI
27/25/27	Tibet Cheezheng Tibetan Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
10/25/10	Tranche Update on Tibet Cheezheng Tibetan Medicine Co., Ltd.'s Equity Buyback Plan announced on March 3, 2025.	CI
16/25/16	Tibet Cheezheng Tibetan Medicine Co., Ltd. Announces Interim Cash Dividend on A Shares for the Year 2025, Payable on 22 September 2025	CI
26/25/26	Tibet Cheezheng Tibetan Medicine Co., Ltd. Proposes Dividend for the First Half of 2025	CI
28/25/28	Tibet Cheezheng Tibetan Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
02/25/02	Tranche Update on Tibet Cheezheng Tibetan Medicine Co., Ltd.'s Equity Buyback Plan announced on March 3, 2025.	CI
29/25/29	Tibet Cheezheng Tibetan Medicine Gets Regulatory Nod for Pediatric Drug Trials	MT
20/25/20	Cheezheng TTM Approves Cash Dividend Distribution for 2024	CI
26/25/26	Tibet Cheezheng Tibetan Medicine Co., Ltd. Proposes Final Cash Dividend for the Year 2024	CI

1 day	-0.35%
1 week	-1.49%
Current month	+0.48%
1 month	-0.90%
3 months	-5.25%
6 months	-13.93%
Current year	-2.37%

Tibet Cheezheng Tibetan Medicine Co., Ltd. Share Price

Equities

002287

CNE100000FM9

Pharmaceuticals

Valuation: Tibet Cheezheng Tibetan Medicine Co., Ltd.

Chart: Tibet Cheezheng Tibetan Medicine Co., Ltd.

Latest news: Tibet Cheezheng Tibetan Medicine Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Tibet Cheezheng Tibetan Medicine Co., Ltd.

Alternative Medicine

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	23.02	23.44
1 month	22.04	23.94
Current year	21.96	25.99
1 year	21.8	38.16
3 years	16.27	38.16
5 years	16.27	38.16
10 years	16.27	50.3

Manager	Title	Age	Since
Xiao Mei Yao DFI	Director of Finance/CFO	56	-
Kai Lie Liu PSD	President	62	25/01/2010
Yi Rui Wang AUD	Comptroller/Controller/Auditor	41	26/09/2019

Director	Title	Age	Since
Ju Fang Lei CHM	Chairman	73	08/10/2007
De An Guo BRD	Director/Board Member	64	13/07/2022
Yu Rong Wang BRD	Director/Board Member	50	21/12/2020

	2023	2024
Net sales	204.52Cr 30Cr 26Cr 23Cr 22Cr 41Cr 2.81TCr 42Cr 275.35Cr 108.47Cr 1.35TCr 112.36Cr 110.05Cr 4.78TCr	233.8Cr 34Cr 29Cr 27Cr 25Cr 47Cr 3.21TCr 48Cr 314.77Cr 124Cr 1.54TCr 128.45Cr 125.81Cr 5.46TCr
Net income	58Cr 8.51Cr 7.26Cr 6.66Cr 6.3Cr 12Cr 798.51Cr 12Cr 78Cr 31Cr 382.47Cr 32Cr 31Cr 1.36TCr	58Cr 8.53Cr 7.28Cr 6.68Cr 6.31Cr 12Cr 799.99Cr 12Cr 78Cr 31Cr 383.19Cr 32Cr 31Cr 1.36TCr
Net Debt	-83Cr -12Cr -10Cr -9.53Cr -9.01Cr -17Cr -1.14TCr -17Cr -111.92Cr -44Cr -547.05Cr -46Cr -45Cr -1.94TCr	-129.88Cr -19Cr -16Cr -15Cr -14Cr -26Cr -1.78TCr -27Cr -174.86Cr -69Cr -854.7Cr -71Cr -70Cr -3.03TCr

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-0.35%	-1.49%	-5.71%	-12.27%	193.53Cr
YUNNAN BAIYAO GROUP CO.,LTD	-1.05%	-2.23%	-6.21%	-0.89%	1.44TCr
BEIJING TONGRENTANG CO., LTD	-0.61%	-1.53%	-25.27%	-49.85%	558.8Cr
DONG-E-E-JIAO CO., LTD.	-1.48%	-5.19%	-16.73%	+4.32%	501.13Cr
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-0.42%	-2.48%	+33.61%	-0.69%	404.63Cr
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	+0.98%	-2.37%	+21.25%	-46.53%	400.01Cr
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	+0.08%	-1.66%	-4.82%	-21.59%	335.94Cr
TASLY PHARMACEUTICAL GROUP CO., LTD	-0.07%	-1.54%	-7.72%	-8.50%	309.06Cr
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-0.42%	-3.41%	+11.16%	-19.10%	255.12Cr
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	-0.09%	-0.37%	-5.28%	+34.42%	177.85Cr
Average	-0.34%	-2.06%	-0.57%	-12.07%	457.65Cr
Weighted average by Cap.	-0.56%	-2.25%	-2.74%	-12.43%